DNTH
Dianthus Therapeutics Inc

1,239
Mkt Cap
$1.9B
Volume
431,042.00
52W High
$45.46
52W Low
$13.37
PE Ratio
-12.67
DNTH Fundamentals
Price
$44.26
Prev Close
$44.71
Open
$44.96
50D MA
$37.56
Beta
0.99
Avg. Volume
779,515.74
EPS (Annual)
-$2.55
P/B
3.47
Rev/Employee
$79,935.90
Loading...
Loading...
News
all
press releases
Dianthus Therapeutics (NASDAQ:DNTH) CFO Sells $903,600.00 in Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, December 4th. The shares were sold at an...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High - Should You Buy...
MarketBeat·22h ago
News Placeholder
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd
XTX Topco Ltd bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·1d ago
News Placeholder
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Geode Capital Management LLC decreased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 6.2% in the 2nd quarter, according to the company in its most recent Form...
MarketBeat·1d ago
News Placeholder
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH
Ensign Peak Advisors Inc bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·8d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High - Here's What Happened...
MarketBeat·11d ago
News Placeholder
Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH
Candriam S.C.A. cut its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 3.2% in the second quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·19d ago
News Placeholder
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the stock, MarketBeat Ratings reports...
MarketBeat·19d ago
News Placeholder
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 87,507 shares of the company's stock in a transaction on Thursday, November 13th. The shares were sold at an...
MarketBeat·19d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 109,031 shares of the firm's stock in a transaction dated Friday, November 14th. The shares were sold at an...
MarketBeat·19d ago

Latest DNTH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.